An interventional study of Innovative diagnostic technologies and Reference diagnostic technique in Bacteremia, sponsored by Centre Hospitalier Universitaire de Nīmes. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Diagnostic
Among 33 studies in Bacteremia with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Bacteremia · France.
Among the 33 studies in Bacteremia with a site in France, this one is the 11th largest by enrollment of the 15 interventional ones, is the only one that started in 2023, is one of 11 with no phase, and was the 23rd registered.
297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.
This study's enrollment of 100 is below the median of 156 across 156 interventional studies indexed under Bacteremia.
Browse Bacteremia studies →7 of the 33 studies in Bacteremia with a site in France are open now, in 5 countries. Each count lists the studies.
Of the 40 Bacteremia studies recruiting now, 32 (80%) set no upper age limit and 4 (10%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →33 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2023.
Median enrollment 200 across the 15 interventional studies, 200 across the 18 observational. Of the 23 that completed or were terminated, 1 (4%) have results posted.
2 of 33 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 90 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 2 studies filed under Bacteremia — fewer than ten, so there is no comparison to draw.
2 of the studies in Bacteremia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07859852Deepull Diagnostics S.L.Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test | 2027-04 |
| NCT06838598Centre Hospitalier William Morey - Chalon sur SaôneStructural and Microbiological Characterization of Arterial Catheter Biofilm in ICU's Patients Using Optical Coherence Tomography | 2027-11 |
Among the 33 studies in Bacteremia with a site in France, from their registry updates:
Bacteremia is a frequent infection in intensive care units. It is associated with a high mortality rate and the rapid implementation of appropriate antibiotic therapy is strongly correlated to patient clinical outcomes.
Innovative technologies have emerged to shorten the turnaround time of blood culture samples by obtaining susceptibility testing of the incriminated pathogen at an early stage, and therefore to rapidly adjust the antibiotic therapy of patients with Gram-negative Bacilli bacteremia.
The study investigators hypothesize that the implementation of the innovative BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® solutions for the analysis of blood culture samples will increase the proportion of patients with Gram-negative Bacilli bacteremia who receive appropriate and optimized antibiotic therapy 24 hours after blood culture collection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the 'after' section of the study only:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Innovative diagnostic technologies · Diagnostic Test: Reference diagnostic technique
Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
Proportion of patients receiving optimized antibiotic therapy (adequate and narrowest spectrum antibiotic therapy) in patients with Gram-negative bacteremia 24 hours after blood culture samples
Yes/no: receiving optimized antibiotic therapy (effective and narrowest spectrum for the identified pathogen(s)) 24 hours after blood culture collection, before and after implementation of the new diagnostic solutions
Time frame: 24 hours
Time to adapt antibiotic therapy (optimized) based on susceptibility testing between the two periods of the study (before and after the implementation of innovative diagnostic technologies) following the collection of blood cultures
Hours (theoretical and real) between blood culture collection and the first change in antibiotic therapy based on the innovative diagnostic technologies solutions or the conventional susceptibility test
Time frame: 28 Days
Concordance of the REVEAL® rapid antibiotic susceptibility testing technology with reference methods
Categorical Agreement of antibiotics tested by REVEAL® technology compared to the reference method (agar plate susceptibility test)
Time frame: 28 Days
Patient survival
Vital status of patients
Time frame: 28 Days
Length of stay in intensive care unit
Number of days
Time frame: 28 Days
Prevalence rate of multiresistant bacteria between the "before" and "after" periods
Proportion of multiresistant bacteria in each evaluation period
Time frame: 28 Days
Prevalence rate of bacteria which are highly resistant to emerging antibiotics between the "before" and "after" periods
Proportion of bacteria which are highly resistant to emerging antibiotics in each evaluation period
Time frame: 28 Days
cost of the device for the healthcare facility
purchase price of the equipment, depreciation, consumables, additional human time if applicable
Time frame: 28 Days
Compare the amount per patient from the health insurance point of view.
amount associated with the number of days spent in intensive care
Time frame: 28 Days
Ran from Mar 2023 to primary completion in May 2024, 13 months.
Of 34 non-industry interventional studies with no phase under Bacteremia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 13 months is below that.
Counting every sponsor, half of 35 studies reached it within 34 months; a quarter within 13 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →